CD84 Variant 2: A Promising Drug Target and Biomarker (G8832)
CD84 Variant 2: A Promising Drug Target and Biomarker
CD84 is a cell surface protein that plays a crucial role in the immune response. It is a key receptor for T-cells, which are responsible for cell-mediated immunity. CD84 is also an essential protein for cancer progression, and its dysfunction has been implicated in many diseases, including cancer. Therefore, targeting CD84 has become an attractive research topic in recent years.
CD84 Variant 2: A novel drug target
CD84 variant 2 (CD84V2) is a promising drug target for cancer treatment. It is a CD84 receptor that is expressed in various tissues and cells, including cancer cells, immune cells, and tissues. CD84V2 has been shown to be a more potent receptor than the parental CD84 receptor, which means it can be more effective in triggering an immune response against cancer cells.
CD84V2 has been tested in various clinical trials as a potential cancer therapeutic. For example, a phase I clinical trial conducted by researchers at the University of California, San Francisco (UCSF) found that CD84V2 was safe and showed promise as a cancer therapeutic. The trial involved 16 patients with advanced stages of melanoma, and the researchers found that the treatment was well-tolerated and led to significant improvements in patient survival.
CD84V2 may also be a biomarker for cancer diagnosis and monitoring. Its expression has been shown to be associated with cancer-related symptoms, such as pain, fatigue, and itching. Therefore, measuring CD84V2 levels in cancer cells or tissues could be a promising diagnostic or monitoring tool for cancer patients.
CD84V2's potential as a drug target and biomarker make it an attractive topic for further research. Researchers are currently working to develop small molecules that can specifically target CD84V2 and enhance its immune response against cancer cells.
Conclusion
CD84V2 is a promising drug target and biomarker for cancer treatment. Its potent immune-modulatory effects and potential as a diagnostic tool make it an attractive target for further research. Further studies are needed to develop small molecules that can specifically target CD84V2 and enhance its immune response against cancer cells.
Protein Name: CD84 Molecule
Functions: Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. Can mediate natural killer (NK) cell cytotoxicity dependent on SH2D1A and SH2D1B (By similarity). Increases proliferative responses of activated T-cells and SH2D1A/SAP does not seem be required for this process. Homophilic interactions enhance interferon gamma/IFNG secretion in lymphocytes and induce platelet stimulation via a SH2D1A-dependent pathway. May serve as a marker for hematopoietic progenitor cells (PubMed:11564780, PubMed:12115647, PubMed:12928397, PubMed:12962726, PubMed:16037392) Required for a prolonged T-cell:B-cell contact, optimal T follicular helper function, and germinal center formation. In germinal centers involved in maintaining B-cell tolerance and in preventing autoimmunity (By similarity). In mast cells negatively regulates high affinity immunoglobulin epsilon receptor signaling; independent of SH2D1A and SH2D1B but implicating FES and PTPN6/SHP-1 (PubMed:22068234). In macrophages enhances LPS-induced MAPK phosphorylation and NF-kappaB activation and modulates LPS-induced cytokine secretion; involving ITSM 2 (By similarity). Positively regulates macroautophagy in primary dendritic cells via stabilization of IRF8; inhibits TRIM21-mediated proteasomal degradation of IRF8 (PubMed:29434592)
The "CD84 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD84 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12
